Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells.
Angiotensin converting enzyme (ACE) inhibitors have immunomodulatory functions and can suppress a number of proinflammatory, monocyte/macrophage-derived cytokines. Interleukin-12 is a cytokine produced primarily by monocytes and macrophages, which plays an essential role in cell mediated immunity and stimulates the development of T helper type 1 immune responses. In this study, we investigated the ability of ACE inhibitors, captopril and lisinopril, to suppress IL-12 production by human peripheral blood mononuclear cells (PBMC). We show that both ACE inhibitors significantly inhibit production of IL-12 by PBMC stimulated with bacterial lipopolysaccharide (LPS) or Staphylococcus aureus Cowan (SAC). Although both ACE inhibitors also suppressed IFN-gamma production by human anti-CD3/anti-CD28-stimulated T-cells, the addition of exogenous IFN-gamma to the PBMC stimulation medium does not abrogate the ability of ACE inhibitors to suppress IL-12 production. Inhibition of IL-12 was not associated with inhibition of IL-1beta, but correlated with the suppression of ACE. Therefore, suppression of IL-12 may contribute to the immunomodulatory effect of ACE inhibitors and may be responsible for the beneficial effect of captopril and other ACE inhibitors in inflammatory or autoimmune conditions in which IL-12 is involved.
Department of Neurology, University of Pennsylvania Medical Centre, Philadelphia 19104, USA. constantines@ubaclu.unibas.ch
C S
CS
Constantinescu
D B
DB
Goodman
E S
ES
Ventura
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology*; D002478:Cells, Cultured; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007375:Interleukin-1 / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis*; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D017706:Lisinopril / Q000494:pharmacology*; D008213:Lymphocyte Activation; D008934:Mitogens; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D010835:Phytohemagglutinins / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism
D000806:Angiotensin-Converting Enzyme Inhibitors; D007375:Interleukin-1; D008070:Lipopolysaccharides; D008934:Mitogens; D010835:Phytohemagglutinins; D018664:Interleukin-12; D007371:Interferon-gamma; D002216:Captopril; D017706:Lisinopril; D007703:Peptidyl-Dipeptidase A